What the trial was testing
The ETHOS enrolled 8,588 patients with copd. The study was sponsored by Pearl Therapeutics, Inc. and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Triple therapy reduced serious COPD flare-ups by about 1 in 4 compared to standard two-drug inhalers.
The New England journal of medicine · 2020 · NCT02465567
These findings — that triple therapy reduced serious COPD flare-ups by about a quarter versus two-drug inhalers — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 8,588 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with copd, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
If you have moderate to very severe COPD and experience flare-ups, this three-drug inhaler may help you avoid emergency visits and hospital stays better than two-drug options. The treatment combines a steroid with two bronchodilators in one device. This combination is FDA-approved and available now — ask your doctor if switching to triple therapy makes sense for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open copd trials
SWEEP: Shuttle Walking Test for Exercise Evaluation in Pulmonary Resection
This is a prospective observational study that evaluates whether the Shuttle Walking Test (SWT) can predict postoperative symptoms, particularly dyspnea, in patients with chronic respiratory diseases undergoing lung resection. Currently, tools such as DLCO or cardiopulmonary exercise testing (CPET) are used to assess surgical risk and exercise capacity before lung surgery. However, these tests are not always accessible due to equipment limitations or long waiting times. The SWT is a simpler, safer, and more cost-effective alternative that has been recently recognized as a new medical technology in Korea for evaluating exercise capacity. In this study, patients with chronic lung diseases (such as COPD, ILD, or bronchiectasis) who are scheduled to undergo lung resection will perform the SWT before surgery. Their symptoms and quality of life will be assessed through questionnaires before and three months after the surgery. The goal is to determine whether SWT results can help predict postoperative dyspnea and provide useful information for preoperative risk stratification.
Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets
The goal of this study is to examine exacerbations of chronic obstructive pulmonary disease (COPD) caused by a common cold virus called rhinovirus, to identify new treatments. Exacerbations are flare-ups of respiratory symptoms which are a major cause of ill health in people with COPD, and are most commonly caused by viruses. The main questions the study aims to answer are: * What processes in the body occur in response to rhinovirus infection, and do the differences between people with COPD and healthy volunteers explain why people with COPD develop more severe illness and exacerbations? * Can treatments be identified that target these processes to reduce the severity and frequency of exacerbations in people with COPD? The study will compare eligible participants with COPD to healthy volunteers, and will involve intentionally infecting each participant with rhinovirus in a controlled environment. They will undergo baseline investigations prior to infection including a first bronchoscopy. Post-infection each participant will undergo a range of tests, including a second bronchoscopy, to compare how processes in the body, and especially the lungs, differ between people who do and do not have COPD.